BridgeBio Pharma (BBIO) Profit After Tax (2019 - 2025)
BridgeBio Pharma (BBIO) has disclosed Profit After Tax for 7 consecutive years, with -$194.6 million as the latest value for Q4 2025.
- Quarterly Profit After Tax rose 27.21% to -$194.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$732.9 million through Dec 2025, down 34.89% year-over-year, with the annual reading at -$732.9 million for FY2025, 34.89% down from the prior year.
- Profit After Tax hit -$194.6 million in Q4 2025 for BridgeBio Pharma, down from -$184.9 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$2.6 million in Q2 2022 to a low of -$267.4 million in Q4 2024.
- Historically, Profit After Tax has averaged -$150.0 million across 5 years, with a median of -$162.6 million in 2021.
- Biggest five-year swings in Profit After Tax: skyrocketed 97.49% in 2022 and later plummeted 6179.91% in 2023.
- Year by year, Profit After Tax stood at -$152.3 million in 2021, then rose by 7.69% to -$140.6 million in 2022, then fell by 21.17% to -$170.3 million in 2023, then plummeted by 56.98% to -$267.4 million in 2024, then increased by 27.21% to -$194.6 million in 2025.
- Business Quant data shows Profit After Tax for BBIO at -$194.6 million in Q4 2025, -$184.9 million in Q3 2025, and -$183.8 million in Q2 2025.